A minimal unified model of disease trajectories captures hallmarks of multiple sclerosis

Mathematical Biosciences

Volumn 289, Issue , 2017, Pages 1504-1514

  Kannan, Venkateshan ^a   Kiani, Narsis A ^a   Piehl, Fredrik ^b   Tegner, Jesper ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNE SYSTEM; NEURODEGENERATIVE DISEASES;

AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEMS; CLINICAL CLASSIFICATION; COMPUTATIONAL MODEL; MULTIPLE SCLEROSIS; NEURODEGENERATION; TWO DIMENSIONAL SPACES; UNIFIED MODELING;

NEUROLOGY;

COMPUTER SIMULATION; DISEASE INCIDENCE; HETEROGENEITY; IMMUNE SYSTEM; NERVOUS SYSTEM DISORDER; NUMERICAL MODEL;

ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL CLASSIFICATION; DISEASE COURSE; HUMAN; ILLNESS TRAJECTORY; IMMUNE SYSTEM; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MULTIPLE SCLEROSIS; STOCHASTIC MODEL; CLASSIFICATION; COMPUTER SIMULATION; IMMUNOLOGY; PATHOLOGY; PATHOPHYSIOLOGY;

CENTRAL NERVOUS SYSTEM; COMPUTER SIMULATION; HUMANS; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 85017550154     PISSN: 00255564     EISSN: 18793134     Source Type: Journal    
DOI: 10.1016/j.mbs.2017.03.006     Document Type: Article

References (37)

1. [1] Compston, A., Coles, A., Multiple sclerosis. Lancet 372:9648 (2008), 1502–1517, 10.1016/S0140-6736(08)61620-7 URL: http://www.ncbi.nlm.nih.gov/pubmed/18970977.
2. [2] Dendrou, C.A., Fugger, L., Friese, M.A., Immunopathology of multiple sclerosis. Nat. Rev. Immunol. 15:9 (2015), 545–558, 10.1038/nri3871 URL: http://www.nature.com/doifinder/10.1038/nri3871.
3. [3] Friese, M.A., Schattling, B., Fugger, L., Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat. Rev. Neurol., 10(4), 2014, 10.1038/nrneurol.2014.37 225–38. URL: http://www.nature.com/doifinder/10.1038/nrneurol.2014.37.
4. [4] R. Milo, A. Miller, Revised diagnostic criteria of multiple sclerosis, 2014, doi: 10.1016/j.autrev.2014.01.012.
5. [5] Mahad, D.H., Trapp, B.D., Lassmann, H., Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 14:2 (2015), 183–193, 10.1016/S1474-4422(14)70256-X.
6. [6] Lassmann, H., Bruck, W., Lucchinetti, C., Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. 2001, 10.1016/S1471-4914(00)01909-2.
7. [7] Westall, F.C., Histo-clinical variation in multiple sclerosis: heterogeneous proteolytic immunogenic processing. Med. Hypotheses 66:3 (2006), 566–569, 10.1016/j.mehy.2005.07.035.
8. [8] B.D. Trapp, K.-A. Nave, Multiple Sclerosis: an immune or neurodegenerative disorder?, doi: 10.1146/annurev.neuro.30.051606.094313(2008).
9. [9] McFarland, H.F., Martin, R., Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol., 8(9), 2007, 10.1038/ni1507 913–9. URL: http://www.nature.com/doifinder/10.1038/ni1507.
10. [10] Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., Toda, M., Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155:3 (1995), 1151–1164, 10.4049/jimmunol.1201644 URL: http://www.ncbi.nlm.nih.gov/pubmed/7636184.
11. [11] Martinez-Pasamar, S., Abad, E., Moreno, B., Velez de Mendizabal, N., Martinez-Forero, I., Garcia-Ojalvo, J., Villoslada, P., Dynamic cross-regulation of antigen-specific effector and regulatory T cell subpopulations and microglia in brain autoimmunity. BMC Syst. Biol., 7, 2013, 34, 10.1186/1752-0509-7-34 URL: http://www.ncbi.nlm.nih.gov/pubmed/23618467.
12. [12] J. Carneiro, K. Leon, Í. Caramalho, C. Van Den Dool, R. Gardner, V. Oliveira, M.L. Bergman, N. Sepúlveda, T. Paixão, J. Faro, J. Demengeot, When three is not a crowd: a crossregulation model of the dynamics and repertoire selection of regulatory CD4+ T cells, 2007, doi: 10.1111/j.1600-065X.2007.00487.x.
13. [13] Brück, W., The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J. Neurol., 252, 2005, Steinkopff-Verlag, v3–v9, 10.1007/s00415-005-5002-7 URL: http://link.springer.com/10.1007/s00415-005-5002-7.
14. [14] Chari, D.M., Remyelination in multiple sclerosis. Mult. Scler., 3, 2007, SAGE Publications, 589–620, 10.1016/S0074-7742(07)79026-8 URL: http://msj.sagepub.com/cgi/doi/10.1177/135245859700300213.
15. [15] Di Ventura, B., Lemerle, C., Michalodimitrakis, K., Serrano, L., From in vivo to in silico biology and back. Nature 443:7111 (2006), 527–533, 10.1038/nature05127 URL: http://www.nature.com/doifinder/10.1038/nature05127.
16. [16] Viglietta, V., Baecher-Allan, C., Weiner, H.L., Hafler, D.A., Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med., 199(7), 2004, 10.1084/jem.20031579 971–9. URL: http://www.jem.org/lookup/doi/10.1084/jem.20031579.
17. [17] Venken, K., Hellings, N., Thewissen, M., Somers, V., Hensen, K., Rummens, J.L., Medaer, R., Hupperts, R., Stinissen, P., Compromised CD4+ CD25high regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 123:1 (2008), 79–89, 10.1111/j.1365-2567.2007.02690.x.
18. [18] Coles, A.J., Wing, M.G., Molyneux, P., Paolillo, A., Davie, C.M., Hale, G., Miller, D., Waldmann, H., Compston, A., Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. 46:3 (1999), 296–304 10.1002/1531-8249(199909)46:3:296::AID-ANA4:3.0.CO; URL: http://www.ncbi.nlm.nih.gov/pubmed/10482259.
19. [19] Ge, Y., Grossman, R.I., Udupa, J.K., Wei, L., Mannon, L.J., Polansky, M., Kolson, D.L., Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. Radiology 214:3 (2000), 665–670, 10.1148/radiology.214.3.r00mr30665 URL: http://pubs.rsna.org/doi/abs/10.1148/radiology.214.3.r00mr30665.
20. [20] Stevenson, V.L., Smith, S.M., Matthews, P.M., Miller, D.H., Thompson, A.J., Monitoring disease activity and progression in primary progressive multiple sclerosis using MRI: sub-voxel registration to identify lesion changes and to detect cerebral atrophy. J. Neurol. 249:2 (2002), 171–177, 10.1007/PL00007860 URL: http://link.springer.com/10.1007/PL00007860.
21. [21] Koshland, D.E., Goldbeter, A., Stock, J.B., Amplification and adaptation in regulatory and sensory systems. Science 217:4556 (1982), 220–225, 10.1126/science.7089556 URL: http://www.ncbi.nlm.nih.gov/pubmed/7089556.
22. [22] Tullman, M., Oshinsky, R., Lublin, F., Cutter, G., Clinical characteristics of progressive relapsing multiple sclerosis. Mult. Scler. 10:4 (2004), 451–454, 10.1191/1352458504ms1059oa URL: http://msj.sagepub.com/cgi/doi/10.1191/1352458504ms1059oa.
23. [23] Confavreux, C., Vukusic, S., Natural history of multiple sclerosis: a unifying concept. Brain 129:3 (2006), 606–616, 10.1093/brain/awl007 URL: http://www.ncbi.nlm.nih.gov/pubmed/16415308.
24. [24] Scalfari, A., Neuhaus, A., Daumer, M., Muraro, P.A., Ebers, G.C., Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 85:1 (2014), 67–75, 10.1136/jnnp-2012-304333 URL: http://www.ncbi.nlm.nih.gov/pubmed/23486991.
25. [25] Amato, M.P., Ponziani, G., A prospective study on the prognosis of multiple sclerosis. Neurol. Sci. 21:0 (2000), S831–838, 10.1007/s100720070021 URL: http://link.springer.com/10.1007/s100720070021.
26. [26] Feinstein, A., Freeman, J., Lo, A.C., Treatment of progressive multiple sclerosis: what works, what does not, and what is needed. Lancet Neurol. 14:2 (2015), 194–207, 10.1016/S1474-4422(14)70231-5.
27. [27] D.H. Miller, S.M. Leary, Primary-progressive multiple sclerosis, 2007, doi: 10.1016/S1474-4422(07)70243-0URL: http://www.ncbi.nlm.nih.gov/pubmed/17884680.
28. [28] Grenfell, B.T., Williams, C.S., Bjørnstad, O.N., Banavar, J.R., Simplifying biological complexity. Nat. Phys. 2:4 (2006), 212–214, 10.1038/nphys231 URL: http://www.nature.com/doifinder/10.1038/nphys231.
29. [29] Pennisi, M., Rajput, A.-M., Toldo, L., Pappalardo, F., Agent based modeling of Treg-Teff cross regulation in relapsing-remitting multiple sclerosis. BMC Bioinf., 14(Suppl 16), 2013, S9, 10.1186/1471-2105-14-S16-S9 URL: http://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-14-S16-S9.
30. [30] Mohan, T.R.K., Sen, S., Ramanathan, M., A computational model for lesion dynamics in multiple sclerosis of the brain. Int. J. Mod. Phys. E 17:05 (2008), 930–939, 10.1142/S0218301308010271 URL: http://www.worldscientific.com/doi/abs/10.1142/S0218301308010271.
31. [31] J. Stark, C. Chan, A.J.T. George, Oscillations in the immune system, 2007, doi: 10.1111/j.1600-065X.2007.00501.x.
32. [32] Korn, T., Reddy, J., Gao, W., Bettelli, E., Awasthi, A., Petersen, T.R., Bäckström, B.T., Sobel, R.A., Wucherpfennig, K.W., Strom, T.B., Oukka, M., Kuchroo, V.K., Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat. Med., 13(4), 2007, 10.1038/nm1564 423–31. URL: http://www.nature.com/doifinder/10.1038/nm1564.
33. [33] Wehrens, E.J., Mijnheer, G., Duurland, C.L., Klein, M., Meerding, J., Van Loosdregt, J., De Jager, W., Sawitzki, B., Coffer, P.J., Vastert, B., Prakken, B.J., Van Wijk, F., Functional human regulatory T cells fail to control autoimmune inflammation due to PKB/c-akt hyperactivation in effector cells. Blood 118:13 (2011), 3538–3548, 10.1182/blood-2010-12-328187 URL: http://www.ncbi.nlm.nih.gov/pubmed/21828127.
34. [34] Jongen, P.J., Lamers, K.J., Doesburg, W.H., Lemmens, W.a., Hommes, O.R., Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary progressive multiple sclerosis. J. Neurol. Neurosurg. Psychiatry, 63(4), 1997, 10.1136/jnnp.63.4.446 446–51. URL: http://jnnp.bmj.com/cgi/doi/10.1136/jnnp.63.4.446.
35. [35] L.K. Peterson, R.S. Fujinami, Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis, 2007, doi: 10.1016/j.jneuroim.2006.11.015.
36. [36] Brex, P.A., Ciccarelli, O., O'Riordan, J.I., Sailer, M., Thompson, A.J., Miller, D.H., A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl. J. Med. 346:3 (2002), 158–164, 10.1056/NEJMoa011341 URL: http://www.ncbi.nlm.nih.gov/pubmed/11796849.
37. [37] Bjartmar, C., Wujek, J.R., Trapp, B.D., Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. 2003, 10.1016/S0022-510X(02)00069-2.